Activity Summary:
Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this live, interactive webcast, Dr. Jean Elwing and Dr. Oksana Shlobin will discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.

This webcast aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will also include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through expert-led presentations and interactive Q&A sessions, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.

Activity Summary:
Pulmonary Arterial Hypertension (PAH) poses significant clinical challenges due to its complex nature and the risk of rapid disease progression. This educational slide kit addresses some of these complex challenges by focusing on two key patient scenarios: a newly diagnosed PAH patient and a high-risk patient with inadequate response to current treatments. These cases emphasize the importance of selecting the appropriate initial treatment regimens and highlights the routine follow-up measures necessary to prevent clinical deterioration.

The slide kit aims to equip clinicians with the skills to recognize parameters associated with disease progression and to make informed decisions about treatment modifications for high-risk patients. By exploring evidence-based strategies and various treatment options, this educational initiative seeks to enhance clinicians' abilities to manage PAH effectively, ultimately improving patient outcomes.

Activity Summary:
Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational podcasts will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.

Activity Summary:
Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In these mini-modules, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand video presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.

Activity Summary:
Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this podcast episode, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.

Activity Summary:
Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this webcast archive, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.

Activity Summary:
Recent data suggests that PAH is now frequently diagnosed in older patients who often present with cardiovascular (CV) comorbidities. Many patients present with CV comorbidities that are uncontrolled, creating a management dilemma for the treating physician. This slide set presents two case studies discussing the clinical approach as well as how to control comorbidities and their impact on the pulmonary circulation with the best treatment approach for this population.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles, resulting in right heart failure and death within 2-3 years of diagnosis if untreated. Despite advances in the diagnosis and treatment of PAH over the last two decades, the prognosis is still poor. Early recognition of disease, institution of effective PAH disease-specific therapy optimized for disease severity, and comprehensive care in specialized centers hold the promise of improving the outcome of patients. PAH is often misdiagnosed or unrecognized in clinical practice and delaying treatment options can worsen outcomes and survival. Diagnostic tests are needed to be done on anyone with unexplained dyspnea and suspected PAH. This slide kit is designed for primary care providers and other non-specialists, using case-based, interactive discussion on tools to improve diagnosis of PAH and the importance of early referral.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
PH is currently divided into World Health Organization (WHO) groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This slide set presents the latest research in diagnosing and managing Group 2-5 in patients, including a discussion of the distinctions in specific groups – CTEPH, PH-ILD, PH-COPD.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

The incidence of PH is known to increase among patients with ILD over the course of disease, however, there is a significant overlap of symptoms between fibrotic lung disease and PH. This is known to result in delayed detection and diagnosis. Clinicians need education on the signs and symptoms and how to screen for and detect PH early among patients with ILD. Although right heart catheterization is required to confirm the diagnosis of PH-ILD, other non-invasive and invasive approaches are useful in enabling an early and accurate diagnosis. Additionally, while there have been new insights into assessing and predicting the severity of PH among patients with ILD, mild PH among patients with ILD has been associated with poor outcomes. Identifying patients that have mild PH is therefore pivotal to improving outcomes with treatment. The development and approval of inhaled treprostinil has been an important milestone in PH-ILD. Indeed, new evidence and updates from ongoing clinical trials continue to be presented and published for the treatment of PH-ILD. To improve confidence among practitioners regarding the use of inhaled treprostinil, it is critical that they are abreast with the latest evidence and expert insights. In this on-demand video presentation Dr. Aaron Waxman will walk through examples of using and optimizing inhaled treprostinil therapy in clinical cases.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. The Lecture Library offers various topics that can be accessed for AMA, ANCC or ACPE credit. Select your topic of interest and complete the pre/posttest and evaluation.

Continue to visit the Lecture Library series throughout 2024 to view updates from new publications and conference updates. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a podcast discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a roundtable discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

This activity is supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
Talking COPD is a webcast series that highlights the very latest clinical data in chronic obstructive pulmonary disease. Slides are developed and presented by leading COPD expert physicians and further reviewed and approved by the planning committee.

Chronic obstructive pulmonary disease (COPD) imposes significant impact beyond the lungs, including quality of life, health status, daily activities, physical activity, sleep, and comorbidities such as anxiety and depression. Given the increasing recognition of, and importance attributed to, patients’ and caregivers’ views and preferences on their disease and its management, it is important to identify and understand patients’ perception of COPD symptoms. Additionally, diagnosis and treatment of COPD are rapidly changing. In this on-demand video presentation, our expert faculty review how the understanding and implementation of recent advances is important for delivering optimal patient care.

Activity Summary:
The Pulmonary Hypertension Association (PHA)-Accredited PH Care Centers (PHCC) program began in late 2011 with the goal to raise the overall quality of care and improve outcomes in patients with this life-threatening disease. Accreditation is based on a center’s overall commitment to PH patients, breadth of health care professionals involved and scope of services provided. Two types of centers will be accredited: Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP). Both will have demonstrated a commitment to providing expert-level care based on published consensus guidelines. PHCCs have the opportunity to enroll PH patients into the Pulmonary Hypertension Association Registry (PHAR) patient registry to evaluate trends and practice patterns to determine which treatments work best. Moreover, in the past two decades, research has vastly improved the understanding of the pathophysiology, diagnosis, and treatment of PAH. While no therapies have been approved to target new mechanisms of action in more than 15 years, multiple phase 2 and phase 3 clinical trials of novel therapies are underway. Therapeutic trials represent the front line of clinical progress, and becoming a clinical trial investigator in PH can further help deliver more life-changing therapies to patients with PH who need them.

This AMA/ANCC/ACPE accredited, on-demand video addresses some key questions on accredited PH Care Centers and what it takes to become a clinical trial investigator.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate despite advances in diagnostic and therapeutic strategies. In recent years, significant scientific progress has been made in the understanding of the underlying pathobiological mechanisms with novel therapeutic compounds in development. In this on-demand video presentation, our PAH experts will review practice-changing results presented at the 2023 ATS, ERS, and CHEST meetings to assess their potential future incorporation into clinical practice for patients with PAH.

Activity Summary:
Clinical Clips are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. This activity is designed to keep healthcare professionals on top of the most recent clinical findings.

This stand alone certified AMA/ANCC/ACPE enduring video will spotlight latest advances in the management of non-small cell lung cancer harboring EGFR Mutations through a 'what you need to know' video featuring a leading expert reporting from the 2023 ESMO Congress.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Honolulu, HI, October 8-11, 2023.

Activity Summary:
Current guidelines recommend initial oral combination therapy for patients with low- or intermediate-risk pulmonary arterial hypertension (PAH) and initial combination therapy including intravenous prostacyclin for high-risk patients. These strategies are based on using regular multiparameter mortality risk assessments and proactive therapy escalation to achieve and maintain a low-risk status. This approach has been shown to slow disease progression, optimize clinical outcomes, and improve survival. Furthermore, as interest towards personalized medicine grows, a comprehensive understanding of patient phenotypes through multiomics approaches, called deep phenotyping, is needed to provide further insights on pathogenesis, diagnosis, prognosis and therapeutic outcomes.

This AMA/ANCC/ACPE accredited, on-demand video addresses some key questions on combination therapy and deep phenotyping featuring a PAH expert answering important commonly asked questions.

Activity Summary:
What’s New Doc? is an accredited, on-demand video presentation featuring a pulmonary arterial hypertension (PAH) expert answering important questions asked about PAH. Two AMA/ANCC/ACPE videos will be launched throughout 2023.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

Pulmonary hypertension among patients with interstitial lung diseases is associated with increased morbidity, mortality, and healthcare burden. To improve outcomes, early detection and treatment of this complication among patients with ILD is an urgent priority. This slide kit will inform and guide on the latest recommendations and methodologies to screen for, detect, and accurately diagnose PH-ILD. The best-practice approaches to further treat and manage patients with PH-ILD will also be detailed. The case-based format will address knowledge and competence deficits among healthcare professionals regarding the diagnosis and treatment of PH-ILD. Overall, this module will narrow or close existing gaps in care to enable improved outcomes among patients with PH-ILD.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Recent progress in pulmonary arterial hypertension (PAH) is based on new strategies for combination therapy and on the escalation of treatments to improve the significant morbidity and mortality associated with this disease. This case-based slide kit is designed to discuss the importance of monitoring patients to determine when and how to optimally alter their PAH therapy. Case 1 discusses a newly diagnosed PAH patient with a review of diagnosis, risk assessments, and initial combination therapy strategies. Case 2 discusses a high-risk PAH patient with a review of disease progression, risk assessment and treatment escalation options.